Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL
December 13, 2021 09:01 ET
|
Fate Therapeutics, Inc.
6 of 10 Patients Naïve to Treatment with Autologous CAR T-cell Therapy Continue in Ongoing Response at Median Follow-up of 9.1 Months, including 4 Patients with >6 Months Follow-up, at ≥90 Million...
Fate Therapeutics to Host Virtual Event at the 2021 ASH Annual Meeting
December 08, 2021 17:44 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics to Present at Upcoming Investor Conferences
November 11, 2021 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
Fate Therapeutics Announces Abstract Highlighting FT538 and FT573 Programs Selected for Presentation at SITC 2021 Annual Meeting Press Conference
November 09, 2021 09:00 ET
|
Fate Therapeutics, Inc.
Company to Host Virtual Investor Event on Monday, November 15 SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company...
Fate Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Operational Progress
November 04, 2021 16:01 ET
|
Fate Therapeutics, Inc.
Initiated Enrollment in Phase 1 Clinical Studies of FT538 and FT576 for R/R Multiple Myeloma FT596 Interim Phase 1 Data of 14 Patients in Single-Dose Escalation Cohorts 2 and 3 for R/R Lymphoma...
Fate Therapeutics Announces Eight Presentations at the 2021 ASH Annual Meeting
November 04, 2021 09:01 ET
|
Fate Therapeutics, Inc.
FT596 Oral and FT516 Poster Presentations to Highlight Updated Clinical Data for Relapsed / Refractory Lymphoma on Monday, December 13 Company to Host Virtual Investor Event on Tuesday, December 14 ...
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2021 Financial Results
October 25, 2021 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting
October 01, 2021 08:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support
September 15, 2021 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics to Present at Upcoming Investor Conferences
September 02, 2021 16:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...